Dana-Farber Cancer Institute Inc

📅 Upcoming

🕒 Recent(90d)

News

• #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
  Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
  endpoints · 2mo ago
• Bristol Myers unveils data for one of its next-gen blood cancer drugs
  Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
  biopharma_dive · 2mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 3mo ago
• Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
  Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.
  onclive · 3mo ago
• Giants of Cancer Care Announces the 14th Annual Class of Inductees
  onclive · 3mo ago
• Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
  Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
  onclive · 3mo ago
• Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
  Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
  onclive · 3mo ago
• Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
  Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
  onclive · 3mo ago
• Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90M
  The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
  fiercebiotech · 7mo ago